TP53 and neoplasm: The anti-tumor effect of statin therapy via inhibition of the mevalonate pathway appears to be restricted to cancers expressing mutant p53, and in breast cancers is further restricted to the hormone receptor negative subtypes (ER-/PR-) [55].